The need to examine metastatic tissue at the time of progression of breast cancer: Is re-biopsy a necessity or a luxury?

Current Oncology Reports

Volumn 13, Issue 1, 2011, Pages 17-25

  Khasraw, Mustafa ^a   Brogi, Edi ^a   Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; ER; Estrogen receptor; HER2; Human epidermal growth factor receptor 2; Metastases; PgR; Progesterone receptor; Tissue biopsy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; ASPIRATION BIOPSY; BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CEP17 GENE; CHROMOSOME 17; DISTANT METASTASIS; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER METASTASIS; METASTASIS; NEEDLE BIOPSY; OVERALL SURVIVAL; PATIENT SELECTION; REPEAT PROCEDURE; REPRODUCIBILITY; TISSUE FIXATION;

BIOPSY; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 79551510050     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0137-9     Document Type: Article

References (50)

1. S Beslija J Bonneterre HJ Burstein, et al. 2009 Third consensus on medical treatment of metastatic breast cancer Ann Oncol 20 1771 1785 1:STN:280:DC%2BD1MjhvVCmtg%3D%3D 10.1093/annonc/mdp261 19608616
2. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 10869 10874 1:CAS:528:DC%2BD3MXntVGmsbo%3D 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
4. CA Hudis 2007 Trastuzumab-mechanism of action and use in clinical practice N Engl J Med 357 39 51 1:CAS:528:DC%2BD2sXnsVygu7s%3D 10.1056/NEJMra043186 17611206 (Pubitemid 47026733)
5. AC Wolff MEH Hammond JN Schwartz, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 1:CAS:528:DC%2BD2sXht1ejs7Y%3D 10.1200/JCO.2006.09.2775 17159189 (Pubitemid 350003059)
6. Hammond ME, Hayes DF, Dowsett M, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010, 134:e48-e72. These are detailed recommended guidelines for ER and PgR testing.
7. D Gancberg A Di Leo F Cardoso, et al. 2002 Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 1036 1043 1:STN:280:DC%2BD38vitFWgtQ%3D%3D 10.1093/annonc/mdf252 12176781
8. Y Gong DJ Booser N Sneige 2005 Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma Cancer 103 1763 1769 1:CAS:528:DC%2BD2MXktFGnsbw%3D 10.1002/cncr.20987 15786420 (Pubitemid 40563246)
9. J Zidan I Dashkovsky C Stayerman, et al. 2005 Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease Br J Cancer 93 552 556 1:CAS:528:DC%2BD2MXpsFalur0%3D 10.1038/sj.bjc.6602738 16106267 (Pubitemid 43079998)
10. E Amir M Clemons 2009 Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 10 933 935 10.1016/S1470-2045(09)70295-5 19796747
11. RJ Broom PA Tang C Simmons, et al. 2009 Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer Anticancer Res 29 1557 1562 19443366
12. Lindström L, Howell S, Âström G, et al.: Controversies in the management of metastatic breast cancer: biologic evaluation of breast cancer-Should metastases be biopsied? In American Society of Clinical Oncology 2010 Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2010:e7-e12.
13. G Kocjan A Chandra P Cross, et al. 2009 BSCC Code of Practice-fine needle aspiration cytology Cytopathology 20 283 296 1:STN:280:DC%2BD1Mnis1ahsg%3D%3D 10.1111/j.1365-2303.2009.00709.x 19754835
14. BJ Youngson M Cranor PP Rosen 1994 Epithelial displacement in surgical breast specimens following needling procedures Am J Surg Pathol 18 896 903 1:STN:280:DyaK2czks1GmtA%3D%3D 10.1097/00000478-199409000-00004 8067510
15. F Liebens B Carly P Cusumano, et al. 2009 Breast cancer seeding associated with core needle biopsies: a systematic review Maturitas 62 113 123 10.1016/j.maturitas.2008.12.002 19167175
16. C Liedtke K Broglio S Moulder, et al. 2009 Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer Ann Oncol 20 1953 1958 1:STN:280:DC%2BD1MjntFOrtQ%3D%3D 10.1093/annonc/mdp263 19596702
17. Murray MP, Liberman L, Nehhozina T, et al.: Negative estrogen receptor and HER2 assays at core biopsy of invasive cancers should be confirmed in the surgical specimens [poster 6008]. Presented at the 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX; December 13, 2009.
18. NS Goldstein M Ferkowicz E Odish, et al. 2003 Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma Am J Clin Pathol 120 86 92 10.1309/QPHDRB00QXGMUQ9N 12866377
19. T Khoury S Sait H Hwang, et al. 2009 Delay to formalin fixation effect on breast biomarkers Mod Pathol 22 1457 1467 1:CAS:528:DC%2BD1MXhtlegsb%2FF 10.1038/modpathol.2009.117 19734848
20. H Mullink SC Henzen-Logmans TM Tadema, et al. 1985 Influence of fixation and decalcification on the immunohistochemical staining of cell-specific markers in paraffin-embedded human bone biopsies J Histochem Cytochem 33 1103 1109 1:CAS:528:DyaL2MXmtFSitrY%3D 2414361
21. KZ Hanley GG Birdsong C Cohen MT Siddiqui 2009 Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations Cancer Cytopathol 117 279 288 10.1002/cncy.20034 19551847
22. AC Wolff ME Hammond JN Schwartz, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 18 43 1:CAS:528:DC%2BD2sXhsVOmu74%3D 19548375
23. GB Mann VD Fahey F Feleppa MR Buchanan 2005 Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer J Clin Oncol 23 5148 5154 10.1200/JCO.2005.02.076 16051956 (Pubitemid 46224023)
24. JA Ibarra LW Rogers A Kyshtoobayeva K Bloom 2010 Fixation time does not affect the expression of estrogen receptor Am J Clin Pathol 133 747 755 10.1309/AJCPPIUHS4GVAR0I 20395521
25. JA Price E Grunfeld PJ Barnes, et al. 2010 Inter-institutional pathology consultations for breast cancer: impact on clinical oncology therapy recommendations Curr Oncol 17 25 32 1:STN:280:DC%2BC3c7jt1emsQ%3D%3D 10.3916/C34-2010-02-02 20179800
26. DJ Slamon GM Clark SG Wong, et al. 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 1:CAS:528:DyaL2sXhtVSht7s%3D 10.1126/science.3798106 3798106
27. A Patil T Nehhozina M Akram, et al. 2008 Clinical, morphologic and immunophenotypic characteristics of breast carcinomas with lung metastasis [abstract 214] Mod Pathol 21 49A
28. • Sauter G, Lee J, Bartlett JM, et al.: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27:1323-1333. This paper addresses biologic and practical aspects related to HER2 testing.
29. C Tapia S Savic U Wagner, et al. 2007 HER2 gene status in primary breast cancers and matched distant metastases Breast Cancer Res 9 R31 10.1186/bcr1676 17511881 (Pubitemid 350215176)
30. A Lipton K Leitzel SM Ali, et al. 2005 Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy Cancer 104 257 263 1:CAS:528:DC%2BD2MXnslymurw%3D 10.1002/cncr.21202 15952182 (Pubitemid 40993251)
31. T D'Alfonso YF Liu S Monni, et al. 2010 Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed Am J Surg Pathol 34 575 581 10.1097/PAS.0b013e3181d65639 20216378
32. EA Mittendorf Y Wu M Scaltriti, et al. 2009 Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes Clin Cancer Res 15 7381 7388 1:CAS:528:DC%2BD1MXhsFSnu7rL 10.1158/1078-0432.CCR- 09-1735 19920100
33. Amir E, Clemons M, Freedman OC, et al.: Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies [abstract]. J Clin Oncol 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2010, 28(May 20 Suppl):1007.
34. C Simmons N Miller W Geddie, et al. 2009 Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20 1499 1504 1:STN:280:DC%2BD1MrnsVaqtg%3D%3D 10.1093/annonc/mdp028 19299408
35. Karlsson E, Lindstrom LS, Wilking U, et al.: Discordance in hormone receptor status in breast cancer during tumor progression [abstract]. J Clin Oncol 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2010, 28(May 20 Suppl):1009.
36. Locatelli M A, Curigliano G, Fumagalli L, et al.: Should liver metastases of breast cancer be biopsied to improve treatment choice? [abstract]. J Clin Oncol 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2010, 28(June 20 Suppl):CRA1008.
37. T Kuukasjarvi J Kononen H Helin, et al. 1996 Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy J Clin Oncol 14 2584 2589 1:CAS:528:DyaK28XlvVGisL0%3D 8823339
38. M Arnedos A Nerurkar P Osin, et al. 2009 Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) Ann Oncol 20 1948 1952 1:STN:280:DC%2BD1MjntFOjsQ%3D%3D 10.1093/annonc/mdp234 19570962
39. A Sharma T Crook A Thompson C Palmieri 2010 Surgical oncology: why biopsying metastatic breast cancer should be routine Nat Rev Clin Oncol 7 72 74 10.1038/nrclinonc.2009.222 20118974
40. A Kalikaki A Koutsopoulos M Trypaki, et al. 2008 Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC Br J Cancer 99 923 929 1:CAS:528:DC%2BD1cXhtV2jurrP 10.1038/sj.bjc.6604629 19238633
41. N Navin A Krasnitz L Rodgers, et al. 2010 Inferring tumor progression from genomic heterogeneity Genome Res 20 68 80 1:CAS:528:DC%2BC3cXls1Omuw%3D%3D 10.1101/gr.099622.109 19903760
42. • Kim MY, Oskarsson T, Acharyya S, et al.: Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326. This interesting basic science paper shows that circulating tumor cells can also colonize their tumors of origin ("tumor self-seeding").
43. SE Monaco MN Nikiforova K Cieply, et al. 2010 A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases Hum Pathol 41 94 102 1:CAS:528:DC%2BD1MXhsFais7%2FO 10.1016/j.humpath.2009.06.019 19740513
44. S Tortola R Steinert M Hantschick, et al. 2001 Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer J Clin Oncol 19 2837 2843 1:CAS:528:DC%2BD3MXltVGgs7g%3D 11387355
45. A Goeze K Schluns G Wolf, et al. 2002 Chromosomal imbalances of primary and metastatic lung adenocarcinomas J Pathol 196 8 16 10.1002/path.1009 11748636 (Pubitemid 34071573)
46. A Nassar A Radhakrishnan IA Cabrero, et al. 2010 Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study Appl Immunohistochem Mol Morphol 18 441 443
47. • Barry WT, Kernagis DN, Dressman HK, et al.: Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol 2010, 28:2198-2206. This paper discusses intratumoral heterogeneity and microarray-based predictions of tumor behavior or clinical outcome.
48. B Weigelt Z Hu X He, et al. 2005 Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer Cancer Res 65 9155 9158 1:CAS:528:DC%2BD2MXhtFWmu77N 10.1158/0008-5472. CAN-05-2553 16230372 (Pubitemid 41507977)
49. R Nahta S Shabaya T Ozbay DL Rowe 2009 Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens Curr Pharmacogenomics Person Med 7 263 274 1:CAS:528:DC%2BC3cXnt1ar 20300449
50. S Di Cosimo J Baselga 2010 Management of breast cancer with targeted agents: importance of heterogeneity [corrected] Nat Rev Clin Oncol 7 139 147 10.1038/nrclinonc.2009.234 20125090